Navigation Links
Reports in Medical Technology

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

CARLSBAD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced its financial results for the quarter ended June 30, 2009. During 2009 Isis has continued to successfully execute its business strategy and as a result reported $669...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

SAN CARLOS, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial results for the second quarter ended June 30, 2009. Net loss for the quarter ended June 30, 2009 was $32.1 million or $0.35 per share, compared to net loss of $...

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

LEXINGTON, Massachusetts, August 3 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company, today reported positive results from the first of three Phase III studies of velaglucerase alfa, its enzyme replacement therapy in development fo...

Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C

PRINCETON, N.J., July 31 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) reported today positive preliminary results from its phase I clinical trial of PSI-7851 for the treatment of hepatitis C (HCV). PSI-7851 is a second generation nucleotide polymerase inhib...

Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms

COLLEGEVILLE, Pa., July 27 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), announced the publication in Fertility and Sterility of data from a Phase 3 clinical study that showed that the investigational compound bazedoxifene/conjugated estrogens...

BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza

BIRMINGHAM, Ala., July 17 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced positive results from two Phase 3 studies of intravenous (i.v.) peramivir in patients with seasonal influenza. The studies were sponsored by BioCryst's partner Shionogi & Co.,...

Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer

MARSEILLE, France, July 10 /PRNewswire-FirstCall/ -- Ipsogen SA (Alternext: ALIPS) today reported that the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer indicated for the first time that the Genomic Grade could be considered as an adjunct to the histolo...

BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis

TURKU, Finland, July 3 /PRNewswire/ -- BioCis Pharma Ltd., a privately held drug development company with its headquarters in Turku, Finland, announced positive results from its Phase IIa clinical trial of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology. This dou...

PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans

MONTEREY, Calif., June 2 /PRNewswire/ -- This month's Journal of Aerosol Medicine and Pulmonary Drug Delivery features positive Phase Ib clinical trial results for PARI Pharma's L-CsA, inhaled liposomal cyclosporine A. In May, PARI Pharma received Orphan Drug Designation from the Food and Drug Ad...

Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

KRX-0401 + Capecitabine More Than Doubled Time to Progression and Overall Response Rate as well as Extended Overall Survival vs. Capecitabine + Placebo in Patients with 2nd or 3rd Line Metastatic Colon Cancer NEW YORK, May 31 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: ...

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

KRX-0401 Demonstrates Impressive Single Agent Efficacy in Patients who Progressed after Failing Treatment Either with a VEGF Receptor Inhibitor or after Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor NEW YORK, May 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, I...

Spherix Reports First Quarter 2009 Earnings

BETHESDA, Md., May 14 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX ), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today reported results for the...

Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientific's TAXUS(R) Liberte(R) Stent

Authors identify important differences between drug-eluting stent brands NATICK, Mass., May 11 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed the publication of an article in the current edition of the Journal of American College of Cardiology (JACC) rev...

BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results

BIRMINGHAM, Ala., May 8 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced that, based on discussions with the U.S. Department of Health and Human Services/Biomedical Advanced Research and Development Authority (HHS-BARDA), it is preparing a portion of its i...

Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status

Conference Call Scheduled for Today - Thursday, May 7, 2009 at 5:30 p.m. Eastern Time MOUNTAIN VIEW, Calif., May 7 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) reported today financial results for the quarter ended March 31, 2009, and provided an update on its prod...

Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update

- Conference Call Today at 5:00 p.m. Eastern Time - SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today reported financial results for the first quarter ended March 31, 2009, and ...

Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis

PARIS, May 4 /PRNewswire/ -- Fovea Pharmaceuticals announced today positive results from its clinical proof-of-concept trial to assess the therapeutic effect of Prednisporin(TM) (FOV1101) in patients with persistent allergic conjunctivitis. Prednisporin(TM) had the same efficacy and a better ...

Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine

EMERYVILLE, Calif., May 1 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), today announced it has received a quarterly royalty payment of approximately $1.5 million from Merz Pharmaceuticals GmbH (Merz) for sales of Memantine for the treatment of Alzheimer's...

Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams

SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE) , a San Diego based medical device company, announced today that Iowa's Des Moines Register published an article reporting that its LUMA cervical imaging system is enhancing the effectiveness of cancer ...

Clinician Reports Fast Healing of Intractable Wounds Using MEDIHONEY(R)

Jason Hanft of Baptist Health South Florida Reports on 11 Patients at SAWC PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Derma Sciences (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced that yesterday at the annual Symposium on the Advances in W...

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results

Conference Call and Webcast at 11:00 a.m. Eastern Time THE WOODLANDS, Texas, April 28 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its...

Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C

- With half as many injections, in two pivotal Phase 3 trials, Albuferon (albinterferon alfa-2b) met the primary efficacy endpoint of sustained virologic response comparable to Pegasys (peginterferon alfa-2a) - - Patients receiving 900-mcg Albuferon had comparable rates of serious and...

An Independent Study Reports on the Utility of ImmuKnow(R), the Cylex(TM) Immune Cell Function Assay, for Monitoring Heart Transplant Recipients

The results of the largest study performed to date will be presented during the International Society for Heart and Lung Transplantation Annual Meeting in Paris, France on April 24, 2009 COLUMBIA, Md., April 24 /PRNewswire/ -- Since it was cleared as an in vitro assessment of cell-mediate...

InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)

- Results inform selection of doses, regimens to be explored in Phase 2b study - -- Phase 2b program anticipated to begin in summer 2009 -- COPENHAGEN , April 24 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that results from a 14-day Phase 1b clinical stu...

Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication

Study shows Clonicel(R) and stimulants combined provide greater improvement in symptoms than stimulants alone DURHAM, N.C., April 23 /PRNewswire/ -- Addrenex Pharmaceuticals, Inc. today announced positive results from a second phase 3 trial of Clonicel demonstrating that the combination of Cl...

Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial

- Updated Data from Initial Cohort Shows 11 of 17 Evaluable Patients Receiving Bavituximab in Combination with Carboplatin + Paclitaxel Achieved an Objective Tumor Response - - Patient Dosing Initiated in Expansion Stage of Trial with Target of Enrolling 49 Patients Overall - TUSTIN, Cal...

Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack

SAN DIEGO, March 27 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM ) today reported on an NIH-funded, pre-clinical study conducted by independent researchers at the University of Cincinnati entitled IGF-1--Overexpressing Mesenchymal Stem Cells Accelerate Bone Marrow Stem Cell ...

Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update

- Conference Call Today at 5:00 p.m. Eastern Time - SOUTH SAN FRANCISCO, Calif., March 16 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today reported financial results for the fourth quarter and year ended Decembe...

DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program

CUPERTINO, Calif., March 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX ) announced today positive results from a 74 patient Phase IIb clinical trial conducted by Endo Pharmaceuticals of TRANSDUR(TM)-Sufentanil, a proprietary seven day patch under development for the treatment of ...

ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM) Platform

PARIS, March 16 /PRNewswire-FirstCall/ -- ExonHit Therapeutics (Alternext: ALEHT) today reported the publication in Lancet Oncology of a study conducted by Institut Gustave Roussy, which describes the identification of a deregulated cell function in breast cancer through the analysis of altern...

Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study

ATLANTA, March 12 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported the interim 12-month safety and efficacy results from the first human ...

Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient

ANN ARBOR, Mich., March 9 /PRNewswire/ -- Terumo Heart, Inc. today announced that NewYork-Presbyterian Hospital/ Columbia University Medical Center recently became the second U.S. center, and first in the Northeast, to implant the DuraHeart(TM) Left-Ventricular Assist System as part of the DuraHe...

Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant

-Company Provides Update on Cash Position- -Biologics License Application for Wrinkles/Nasolabial Folds Indication Expected To Be Filed Within Two Weeks- EXTON, Pa., March 5 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE ) announced today positive top-line efficacy results ...

Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting

New subset analysis of bortezomib-relapsed patient population demonstrates 55% overall response rate and extended time to progression NEW YORK, Feb. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced updated clinical results from an ongoing Phase 1/2...

ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease

PARIS, February 26 /PRNewswire-FirstCall/ -- ExonHit Therapeutics (Alternext: ALEHT) is pleased to announce that clinical testing of EHT 0202, its lead compound in Alzheimer's disease, is progressing well. Patient enrolment for the Phase IIa trial assessing EHT 0202 in patients with Alzheimer'...

Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate

Results support that Novavax's Recombinant Technology May Offer a Powerful, New Approach for Development of the Next Generation of Influenza Vaccines with Broad Protection Against Multiple Strains ROCKVILLE, Md., Feb. 19 /PRNewswire-FirstCall/ -- NOVAVAX (Nasdaq: NVAX ) announced today favo...

Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer

PHILADELPHIA, and REHOVOT Israel, February 12 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq: ROSG ) reported today the first ever in-vivo efficacy data for a systemic microRNA-based cancer therapeutic. The animal-model study demonstrated a marked suppression of a microRNA that was f...

Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist

FREISING-WEIHENSTEPHAN, Germany, February 3 /PRNewswire/ -- Pieris AG, a biopharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, reports today that it has made significant progress in the development of its Anticalin(R) candidate PRS-050, a pot...

MannKind Reports Successful Completion of Device Bioequivalence Trial

VALENCIA, Calif., Jan. 13 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD ) today announced successful completion of its trial to demonstrate equivalence of its commercial inhaler to the version of the device that was used in clinical trials to deliver AFRESA(TM), MannKind's ultra...

AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety

Results Show Successful Clinical Validation of Pharmacodynamic Effect REDWOOD CITY, Calif., Jan. 12 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc., an emerging specialty pharmaceutical company focused on the treatment of intermittent and acute medical conditions with an initial emphasis on pain...
Other Tags
(Date:2/5/2015)... , 5. Februar 2015 Marken ... Logistikunternehmen und hat eine neue Marketingkampagne gestartet, ... (Clinical Logistics Organization – CLO) der Branche ... lautet First , mit Schwerpunkt auf ... http://photos.prnewswire.com/prnh/20150205/173753 Logo - ...
(Date:2/5/2015)... SAN DIEGO , Jan. 26, 2015   Epic ... treatment of cancer, today announced that Murali Prahalad , ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, ... Mountain View, Calif. on January 26-28, ... entitled, "CTCs Come of Age as Biomarkers." Last year, Epic ...
(Date:2/5/2015)... Jan. 27, 2015   Marvin Test ... deployed, innovative test solutions for military, aerospace, ... of its TS-323 GENASYS Test Platform ... (LMSSC). GENASYS is a high-performance PXI-based system ... applications that require performance functional testing. GENASYS ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:3/4/2015)... March 04, 2015 SIGVARIS ... technology and their first compression therapy collection designed exclusively ... this collection, SIGVARIS USA is proud to announce the ... product line. , Constructed from a unique, extremely fine ... in mind. These socks and thigh-highs offer a tailored ...
(Date:3/4/2015)... According to a new report published ... the U.S. suffer from gastroesophageal reflux disease (GERD), more ... to control acid production, but these can have side ... the problem and lead to other uncomfortable digestive conditions. ... the lower esophageal sphincter does not function properly. Anti-reflux ...
(Date:3/4/2015)... Richey, FL (PRWEB) March 04, 2015 In ... Detox cut the ribbon on their new facility in New ... Chamber of Commerce. The new facility will allow the Florida ... helping end the prescription drug abuse epidemic through treatment and ... reality of drug addiction in the United States, we made ...
(Date:3/4/2015)... 2015 Jeannie Mai, TV personality, fashion maven, ... the cover of the print publication. Mai embraces the overall ... when shopping for clothes and personal care products. In an ... her commitment to an organic diet. She mentions, “Having an ... in gymnastics, but also now as I’m a full time ...
(Date:3/4/2015)... Hoersholm, DK (PRWEB) March 04, 2015 ... of Dako , has joined the Visiopharm ... joins Visiopharm at a time when we are positioned ... quantitative digital pathology for cancer diagnostics and research. ... invested significantly in the development and validation of ONCOtopix™ ...
Breaking Medicine News(10 mins):Health News:Building on the Success of MIDTOWN MICROFIBER, SIGVARIS Expands Popular Compression Collection with Longer Foot Length Offerings 2Health News:New and Proven Acid Reflux Treatments Offer Relief to Millions of Americans 2Health News:New and Proven Acid Reflux Treatments Offer Relief to Millions of Americans 3Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 2Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 3Health News:Visiopharm Appoints Patrik Dahlen as Chairman of the Board 2Health News:Visiopharm Appoints Patrik Dahlen as Chairman of the Board 3
Other Contents